Takeda's Alun­brig wins lung can­cer ap­proval; Atara of­fers an­oth­er pos­i­tive MS drug up­date

→ Take­da’s ty­ro­sine ki­nase in­hibitor briga­tinib (brand­ed Alun­brig) — a drug the Japan­ese drug­mak­er ac­quired with its $5.2 bil­lion Ari­ad buy­out — has se­cured ap­proval for a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER